Granules recalls over 2.3 crore Ranitidine tablets

Granules India Ltd. has initiated a voluntary recall of over 2.3 crore tablets of Ranitidine 150 mg in the US market because of the presence of carcinogen N-nitrosodimethylamine (NDMA) in the active pharmaceutical ingredient (API), used for making the anti-acidity medicine. The recall, which was initiated on December 13, 2019, and is ongoing, has been classified as Class-II by US Food & Drug Administration (USFDA).